Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?

Chenyu Zhang and Dihua Yu

Abstract
Recent breakthroughs in cancer immunotherapy have led to curative efficacy and significantly prolonged survival in a subset of patients of multiple cancer types; and immunotherapy has become the newest pillar of cancer treatment in addition to surgery, chemotherapy, radiotherapy and precision targeted therapies. In the metastatic disease setting, responses to immunotherapy are heterogeneous depending on the metastatic organ sites. The tissue-specific immuno-biology in the tumor microenvironments (TMEs) contributes to the differential therapeutic responses. Herein, we review the impact of tissue-specific tumor microenvironment on the efficacy of immunotherapy, with a focus on historically under-represented central nervous system (CNS) metastasis, which was excluded from most clinical trials. Retrospective examination of patient specimens and prospective clinical studies with immune check-point blockade (ICB) have established that brain can harbor an “active” immune microenvironment for effective immunotherapy. Regulation by the innate immune microglial cells and remodeling of the blood–brain barrier (BBB) may contribute to immunotherapeutic responses mediated by T lymphocytes. How to convert an “inactive” (cold) brain microenvironment into an “active” (hot) brain TME should be the focus of future efforts. Thus, procurement and complete examination of clinical specimens from brain metastases as well as development of appropriate preclinical brain metastasis models susceptible to external manipulation of the TME are critical steps towards that goal. A deeper understanding of the immuno-biology in distinct organ microenvironments will help to expand the benefits of immunotherapy to more needed patients.

Keywords: Immunotherapy, Therapeutic response, Tumor microenvironment, Brain metastasis

Background: immunotherapy
The idea of immunotherapy was conceptualized more than 100 years ago when German pathologist Rudolf Virchow first described the involvement of immune cells in human tumors [1], followed by American surgeon William Coley’s successful attempt to treat cancer patients by inoculating them with “Coley’s toxins”, a preparation of live bacteria that activates cancer patients’ immune system [2]. Even though in the ensuing century Coley’s approach was proven inconsistent and remained controversial, as proof of concept it still established that the human immune system can be utilized to attack cancer cells. Coley is thus widely recognized as the “Father of Cancer Immunotherapy” [3].

Beginning in the 1980s, therapeutic monoclonal antibodies, a bioengineered version of the naturally secreted immune molecule, emerged as a versatile platform of therapeutic agents against cancer [4, 5]. After more than 30 years of development, it has firmly established as a major modality of pharmaceutical agents as > 60 of monoclonal antibodies have been FDA approved for treatment of various human diseases [6]. During the same period another immunotherapy agent, the natural cytokine molecule interleukin-2 (IL-2), emerged as a promising anti-cancer agent and its recombinant form aldesleukin won FDA approval for treating metastatic renal cancer in 1992 [7]. IL-2 is an...
extremely potent and pleiotropic regulator of white blood cell (lymphocyte) activation and key functions of the immune system [8]. However, due to severe side effects, IL-2 has a narrow therapeutic window and its usage is limited only to treating selective advanced melanoma and renal cancer patients [9, 10].

It has long been known that CD8+ effector T cells have cytolytic capability that kills cancer cells [11]. In-depth understanding of the T cell biology took off in the 1980–1990s, which included the discovery of T cell receptors (TCR) [12, 13], identification of positive [14] and negative co-stimulatory molecules [15]. It was then postulated and demonstrated that appropriate manipulation of T cells may exert powerful anti-tumor activity in animal models [16]. After years of preclinical and clinical development, two forms of T cell-based immunotherapy, immune checkpoint blockade (ICB) and adoptive cell transfer (ACT) that includes chimeric antigen receptor T cell (CAR-T) therapy, have shown remarkable clinical efficacy in treating a wide range of advanced cancers [17–19]. These unprecedented results have propelled immunotherapy as the newest modality of cancer treatment in addition to other available therapies [20]. Currently both modalities of T cell-based immunotherapy are the focus of intensive research and clinical development in order to expand efficacy into more cancer types and frontline patient cohorts. While ICB has won FDA approval in a wide range of both solid and liquid cancer types [21], so far ACT therapies have been successful only in hematological malignancies [22]; hence, the current review will focus on ICB therapies because extensive organ-specific interactions between cancer cell and tumor microenvironment (TME) take place primarily in solid tumor metastases.

**Impact of organ-specific tumor microenvironments on immunotherapeutic responses**

Different cancer types tend to colonize specific organ sites, as depicted by the “seed and soil” hypothesis of metastasis [23]. Many of the organ sites have distinctive immune microenvironments typified by the presence of distinct tissue-resident innate immune cells [24], such as osteoclasts in the bone, microglia in the brain, Kupffer cells in the liver, alveolar macrophages in the lung and peritoneal macrophages in the omentum (Table 1). These cells serve as frontline mediators of immune surveillance and local inflammation, as well as an important component of tumor-associated macrophage (TAM). Hence it is not surprising that the tissue-dependent difference is most important in response to immunotherapy.

A common clinical observation with advanced cancer patients is the differential responses to systemic treatments where some metastatic lesions may be less or more responsive to therapy compared to lesions located at other anatomical sites. Such frequently encountered clinical phenomenon strongly suggests that the local TME plays crucial roles in modulating therapeutic responses. For example, in a retrospective study of 371 metastatic melanoma patients treated with the first FDA-approved “modern” immunotherapy high-dose IL-2, the response rate in patients with cutaneous or subcutaneous metastasis was ~50% whereas with visceral metastases it was only 13%; more strikingly, in individual patients harboring both cutaneous/subcutaneous and visceral metastases, tumor regression took place only at cutaneous/subcutaneous lesions whereas visceral metastases progressed upon the same systemic IL-2 therapy [25]. Furthermore, in more recent retrospective studies exploring the relationship between metastases and anti-PD-1 immunotherapy in melanoma and non-small cell lung cancer (NSCLC) patients, it was discovered that the presence or absence of liver metastases was significantly

---

**Table 1 Tissue-resident innate immune cells in common organ sites of metastasis**

| Metastasis target organ | Innate immune cell type | Function and contribution |
|-------------------------|-------------------------|--------------------------|
| Bone                    | Osteoclasts             | Multinucleated cells transformed from monocytes that breaks down and absorbs the bone tissue, critical in the bone homeostasis |
| Brain                   | Microglia               | Myeloid lineage glial cells accounting for 10-15% of all cells in the brain, mediating immune surveillance and inflammation in homeostasis and diseases of the central nervous system |
| Liver                   | Kupffer cells           | Specialized macrophages lining the walls of the liver sinusoids, serving as the primary clearing cell for critical metabolic and detoxification functions of the liver |
| Lung                    | Alveolar macrophages    | High activity macrophages located in pulmonary alveoli, the terminal units of gaseous exchange, primarily responsible for removing respiratory dust and pathogens |
| Omentum                 | Peritoneal macrophages  | Omental milky spot-located macrophage cells playing house-keeping roles in immune surveillance, cell debris clearance and resolution of local inflammation |
associated with reduced objective response rate (ORR, 30.6% vs. 56.3%) and shortened median progression-free survival (mPFS, 5.1 vs. 20.1 months) in melanoma, and was related to a significant difference of progression-free survival (mPFS 1.8 vs. 4.0 months) in NSCLC as well [26, 27].

Despite the clear relevance derived from multiple clinical studies, further in-depth mechanistic investigations that require procuring clinical specimens from multiple metastatic organ sites can be logistically challenging. To that end, an exceptional case study reported a single patient with high-grade serous ovarian cancer who was treated with multiple chemotherapy regimens and exhibited regression of some metastatic lesions with concomitant progression of other lesions [28]. After comprehensive biological profiling of the metastatic lesions, it was found that while the aggressively progressing metastases were characterized by immune cell exclusion, the regresssing and stable metastases were heavily infiltrated by CD8+ and CD4+ T cells and exhibited oligoclonal expansion of specific T cell subsets. This study was a rare but direct examination of clinical samples that unequivocally demonstrated the crucial role of distinct tumor immune microenvironments co-existing within an individual patient and impacting the heterogeneous responses of metastatic lesions to a homogenous systemic therapy [28].

To broadly elucidate the underlying biological mechanisms of the organ specific TME impact on immunotherapy responses, multiple studies have used preclinical murine models harboring metastases at multiple anatomical sites and having treatments by various immunotherapy agents. For example, implanting murine 4T1 mammary cancer cells at subcutaneous or intratibial sites and FACS profiling of isolated tumor-associated immune cells revealed significant differences in the immune composition (macrophages, dendritic cells, CD8+ and CD4+ T cells, etc.) depending on the sites of tumor growth [29]. Additionally, responses to an immunotherapy treatment regimen consisting of three agonist antibodies, Tri-mAb (anti-DR5, anti-CD40 and anti-4-1BB) were compared among multiple pairs of subcutaneous and orthotopic cancer models (renal, colon or prostate) [30]. It was observed that orthotopically implanted tumor lesions responded significantly less to therapy than the same tumor type located subcutaneously. Reimplantation experiments confirmed that tissue specific TME was the determinant of differential responses to therapy. Compared with subcutaneous tumors, orthotopic tumors had a prominent type 2 immuno-suppressive microenvironment. More importantly, causal factors were identified and neutralizing the macrophage- and Th2-associated molecules, e.g. chemokine CCL2 and cytokine IL-13, significantly improved therapeutic responsiveness [30]. Similarly, tissue immune microenvironments were shown to be determinants of differential responses to immunotherapy treatments in other murine models, such as a study using the syngeneic CT26 cells to compare orthotopic colon cancer and subcutaneous cancer lesions [31] and another study using the syngeneic B16F10 murine melanoma cells to compare subcutaneous and lung tumor lesions [32].

Unfortunately, despite fair amount of effort by the research community to compare differential anatomic responses to cancer therapies, the brain, one common metastasis organ site, has been adversely neglected [33, 34]. With better management of systemic diseases and prolonged survival, brain metastasis incidence has kept increasing in multiple cancer types in recent years [35, 36]. Almost all clinical trials exclude patients with CNS metastasis in fear of multiple factors, such as the brain's impermeability to therapeutic agents, and rapid deterioration of patients' status caused by CNS progression [37, 38]. In the following sections of this review, we will discuss the immuno-biology in the CNS microenvironment and its impact on immunotherapy efficacy.

Immuno-biology of the brain microenvironment

While the primary regulatory and cognitive functions of the central nervous system (CNS) are conducted by neuronal circuitry, it is also essential to maintain a homeostatic environment of stable metabolism and inflammation, which tasks fall on the large number of stromal cells in the brain, including astrocytes and microglia cells [39]. To that end, the CNS is shielded from the rest of blood circulation by the presence of blood–brain barrier (BBB) [40] and establishes its own homeostatic regulatory system distinct from other organs in the body [41]. Brain is generally regarded as an immune privileged sanctuary organ site, where immune responses must be tightly regulated to prevent overwhelming and potentially damaging immune reactions [42]. The latest evidence suggests that cells in the brain constantly and actively regulate immune responses; and dysregulation of such regulation may contribute to the pathogenesis of neurodegenerative diseases [43], malignant transformation of glioma [44], and outgrowth of metastatic tumors [45]. Thus, understanding immuno-biology of the distinctive metabolic and inflammatory microenvironment in the CNS is a prerequisite for successful immunotherapy targeting brain metastases.

Intracranial malignant neoplasms can arise either from primary brain tumors (mainly glioma) or from secondary cancers metastatic to the CNS. Lung cancer, breast cancer and melanoma are the major sources of brain metastases, which collectively outnumber primary malignant brain
tumors by ~10:1 [46, 47]. While both gliomas and CNS metastases may share the same anatomical site of tumor growth, similar treatment modalities (surgery, radiation and chemotherapy), devastating impact on quality of life and dismal prognosis, the underlying disease pathogenesis and interaction between tumor cells and shared TME may be vastly different. In primary brain malignancies such as glioblastoma (GBM), up to 30–40% of the tumor mass can be composed of resident and infiltrating myeloid cells [48–50], while tumor-infiltrating lymphocytes (TIL) represents a tiny portion (<0.25%) of cells isolated from human GBM biopsies [51]. In contrast, close examination of host reactions in murine models of breast cancer brain metastasis demonstrated that host astroglial and microglial cells became drastically activated and accumulated around metastatic cells shortly after tumor cell extravasation upon carotid artery injection, suggesting very early involvement of brain defensive mechanism during the metastatic process [52]. The cytokine signaling axis CCL2 up-regulation and recruitment of brain metastasis-mediating monocytes [58] intrinsically recognized as a universal hallmark of cancer and as the mechanism to evade and overcome immune surveillance [60, 61]. Therefore, it is not surprising that infiltration of immune suppressive FOXP3+ regulatory TILs, as well as exhausted PD-1+ TILs, has been observed in the majority of these brain metastasis specimens [59]. Consistently, in a study comparing NSCLC-derived brain metastases and matched primary tumors, PD-L1 expression was more frequently observed in brain metastases than in the matched primary tumors [62].

Lastly, how do adaptive immune T cells infiltrate brain metastatic lesions in the presence of blood–brain barrier (BBB)? Pharmacodynamic studies in preclinical murine models of breast cancer brain metastasis showed that BBB permeability could be compromised, and vascular leakiness became highly heterogeneous depending on the progression of brain metastatic outgrowth [63]. Furthermore, a prominent adverse event of CAR-T immunotherapy is cerebral edema (neurotoxicity) caused by massive T cell infiltration into the brain parenchyma [64]. Though the exact mechanism for this severe adverse phenotype remains elusive, it is clear from pathological examination that the BBB is significantly disrupted in these adverse cases [65]. Therefore, the distinctive vascular properties of the CNS and its remodeling under disease conditions also partially contribute to the immunobiology of brain metastasis.

**Response of brain metastasis to immunotherapy and strategies to enhance efficacy**

Brain is conventionally regarded a major organ site of metastasis with sanctuary immune status; hence, up till recently, most clinical trials exclude patients with CNS metastases [37, 38]. With the advent of immunotherapies, particularly the immune checkpoint blockade (ICB), the efficacy of immunotherapy in the context of brain metastasis has been understudied in the clinic; yet it remains an emergent medical need and substantial clinical interest has developed whether ICB could be as effective in managing brain metastasis as its remarkable efficacy in controlling extracranial metastases. The intracranial activity of immunotherapy was first noted in the post hoc analysis of a phase III clinical trial comparing single agent or combination of the anti-CTLA-4 ipilimumab or gp100 peptide vaccine in metastatic melanoma patients (NCT00094653) [17]. This initial signal led to an open-label phase II study of single-agent ipilimumab for patients with melanoma-derived brain metastases [66], which showed modest intracranial activity. At the same
time, despite exclusion of patients with CNS metastases in all of the early clinical trials targeting another immune checkpoint PD-1/PD-L1 pathway, a single-center phase II study of anti-PD-1 pembrolizumab in patients with melanoma and NSCLC-derived brain metastases showed promising results [67].

Based on these clinical studies showing early signals of positive intracranial activity, a landmark trial of treating melanoma brain metastasis with ICB combination of anti-PD-1 nivolumab and anti-CTLA-4 ipilimumab has been conducted (CheckMate 204, NCT02320058) [68]. It was an open-label phase II study of patients with untreated melanoma brain metastasis, which led to remarkable clinical efficacy showing intracranial clinical benefit rate (primary end point) of 57% among the 94 patients being evaluated.

Despite these promising results, the advances are still in the early stage and most patients with CNS metastases remain difficult to treat; the benefit must also be extended to brain metastases from other primary cancer types in addition to melanoma. Additionally, the underlying mechanism of resistance versus response of the intracranial tumors to systemically administered ICB remains a fundamentally unanswered question. Because immune cells are highly dynamic in response to physiological alterations, their biological functions must be tightly coupled to the cellular metabolism that provides the underlying material and energetic support. From in vitro studies, it was believed that activation of T cells shifts cellular metabolism towards glycolysis which takes place in the cytosol and produces more biological building blocks in preparation of cell proliferation and clonal expansion, and that naïve and memory T cells are more dependent on mitochondrion-dependent oxidative phosphorylation (OXPHOS) which yields more ATP to confer higher spare respiratory capacity [69]. However, a recent study showed that in vivo isolated TIL cells, whose immune effector functions are impaired, gradually lose OXPHOS activity by progressive loss of PPAR-gamma coactivator 1α (PGC1α), a master transcriptional regulator of mitochondrial biogenesis, and that metabolic reprogramming of OXPHOS through forced expression of PGC1α restores and enhances the T cell cytolytic activities [70]. Additionally, while OXPHOS is differentially regulated in M1 or M2 macrophages, the T lymphocytes do not shut down OXPHOS during activation but instead significantly remodel the mitochondrial proteome [71, 72]. Therefore, mitochondria and its dynamics, which includes opposing fusion and fission processes, have appeared to exert profound influence on effective immunity [73, 74]. At the center of mitochondrial functions, OXPHOS is conducted through five multi-subunit protein complexes lining in the cristae membranes. Individually, these distinct protein complexes also participate in various inflammatory regulations. For example, reactive oxygen species (ROS) are potent mediators of inflammation, which are mainly produced by complexes I and III of the OXPHOS chain [75]. Further, succinate is a metabolite with important inflammatory signaling functions, whose conversion to fumarate is mediated by succinate dehydrogenase, complex II of the OXPHOS cascade [76]. Given the unique metabolic microenvironment in the brain [77], it is reasonable to speculate that brain specific metabolic pathway may modulate response to ICB therapy. Along this line, in another recent study that compared patient-matched melanoma brain metastases and extracranial tumor lesions, it was found that the brain metastatic lesions have significantly lower T cell infiltration (immunosuppressive) and higher OXPHOS activity than those from extracranial tumor specimens. Further, such differences were replicated in multiple human melanoma xenograft models where cancer cells were implanted subcutaneously and intracranially and compared with RNA-seq expression profiling. Importantly, treatment with an in-pipeline OXPHOS complex I inhibitor significantly improved animal survival in multiple preclinical melanoma brain metastasis models [78]. Collectively, these findings suggest that in the brain TME, the metastatic tumor cells are more dependent on mitochondrion mediated OXPHOS metabolism. Since immune cells are also dependent on OXPHOS metabolism for cytolytic effector functions [70], increased OXPHOS metabolic activity in tumor cells may deprive necessary nutrient substrates for infiltrating immune cells and result in an immunosuppressive TME in the CNS metastatic lesions (Fig. 1). It would be clinically impactful to determine whether the increased OXPHOS activity of brain metastatic tumors may causally confer resistance to ICB immunotherapy; and whether overcoming such intracranial metabolic dysregulation by combinatorial targeting of brain specific metabolic pathway and immune checkpoints may further enhance the efficacy of existing immunotherapy.

**Conclusions and future direction**

Currently, immunotherapy benefits a small number of patients across multiple cancer types, and the immunobiological microenvironments at distinct metastatic organ sites are important determinants for differences in efficacy. In particular, the local immuno-biological TME at metastatic organ sites, partly mediated by the tissue-resident innate immune cells, interacts with the systemic adaptive immune system to determine responses to immunotherapy. Therefore, the major goal of future efforts should be deepening the understanding of underlying immuno-biological mechanisms responsible for
the organ-specific anti-tumor immune responses and based on such knowledge developing strategies to expand the benefits of immunotherapy to more patients with advanced metastatic cancer. To that end, it is important to analyze clinical specimens of immunotherapy treated metastases of all cancer types (responders and non-responders, early relapses and long-term survivors) to examine immune cell infiltration and composition, as well as local stromal cell alterations, which will reveal novel insight into the response mechanism of immunotherapy in distinctive metastatic TMEs. Additionally, it is necessary to perform mechanistic studies and functional validations using appropriate animal models in order to better understand the immuno-biology underlying effective immunotherapy.

In the CNS, it has been convincingly established, by retrospective examinations of brain metastasis specimens and prospective clinical studies of ICB treatment of patients with brain metastases, that in some patients the brain can harbor an “active” immune microenvironment that respond to immunotherapy. Enrichment of mitochondrion mediated OXPHOS is a unique metabolic trait of brain metastasis; modulating the OXPHOS activity in the brain TME may impact efficacy of ICB treatments.

To overcome the immunosuppressive TME in the CNS, future efforts should also include combining checkpoint inhibitors with other treatments (radiation, chemotherapy, targeted therapy, oncolytic viruses, etc.). The rapid progress in clinical investigations and preclinical studies will pave the way for effective modulation of the brain metastasis tumor microenvironment that allows effective T cell-mediated responses and enables more brain metastasis patients to benefit from immunotherapy.

In summary, persistent endeavor in clinical investigations and preclinical studies to explore effective ways of manipulating the local immuno-biological microenvironment will likely enhance and expand the efficacy of immunotherapy to more metastatic diseases.

Abbreviations
ACT: adoptive cell transfer; BBB: blood–brain barrier; CAR-T: chimeric antigen receptor T cell; CNS: central nervous system; GBM: glioblastoma; ICB: immune checkpoint blockade; mPFS: median progression-free survival; NSCLC: non-small cell lung cancer; ORR: objective response rate; OXPHOS: oxidative phosphorylation; ROS: reactive oxygen species; TAM: tumor-associated macrophage; TIL: tumor-infiltrating lymphocyte; TME: tumor microenvironment.

Acknowledgements
We thank members of the Yu laboratory for productive discussions, especially Dr. Lin Zhang for helpful advice on artistic drawing of Fig. 1. We apologize for...
not being able to cite all the relevant original research and review articles due to space limitation.

Authors’ contributions
CZ drafted the manuscript. CZ and DY revised the manuscript. CZ prepared the manuscript for submission. Both authors read and approved the final manuscript.

Funding
This work was supported by National Institutes of Health grants R01CA12567-06 (D.Y.), R01CA184836 (D.Y.), R01CA208215 (D.Y.), R21CA223102 (D.Y.), and the China Medical University Research Fund (D.Y.). D. Yu is the Hubert L. & Olive Stringer Distinguished Chair in Basic Science of MD Anderson Cancer Center.

Availability of data and material
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
The authors declare that they have no competing interests.

Received: 19 June 2019 Accepted: 28 September 2019
Published online: 07 October 2019

References
1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.
2. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154–8.
3. Hoplion Cann SA, van Netten JP, van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J. 2003;79(938):672–80.
4. Reichert JM. Monoclonal antibodies in the clinic. Nat Biotechnol. 2001;19(9):819–22.
5. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005;23(9):1073–8.
6. Grilo AL, Mantalaris A. The increasingly human and profitable monoclonal antibody market. Trends Biotechnol. 2019;37(11):9–16.
7. Noble S, Goa KL. Aldesleukin (recombinant interleukin-2). BioDrugs. 1997;9(7):394–422.
8. Ross SH, Cantrell DA. Signaling and function of interleukin-2 in T lymphocytes. Annu Rev Immunol. 2018;36:411–33.
9. Antony GK, Dudek AZ. Interleukin 2 in cancer therapy. Curr Med Chem. 2010;17(29):3297–302.
10. Silva DA, Yu S, Ulge UY, Spangler JB, Jude KM, Labao-Almeida C, Ali LR, Quijano-Rubio A, Ruterbusch M, Leung J, et al. De novo design of potent and selective mimics of IL-2 and IL-15. Nature. 2019;563(7738):186–91.
11. Masopust D, Veysy Y, Wherry EJ, Ahmed R. A brief history of CD8 T cells. Eur J Immunol. 2007;37(7 Suppl 1):S103–10.
12. Yanagi Y, Yoshikai Y, Leggett K, Clark SP, Aleksander I, Mak TW. A human T-cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains. Nature. 1984;308(5955):145–9.
13. Hedrick SM, Cohen DI, Nielsen EA, Davis MM. Isolation of cDNA clones encoding T-cell-specific membrane-associated proteins. Nature. 1984;308(5955):149–53.
14. June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol. 1987;7(12):4472–81.
15. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174(3):561–9.
16. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–6.
17. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassell JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.
18. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–33.
19. Topalian SL, Hodi FS, Brahmer JR, GETTINGER SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.
20. McCune JS. Rapid advances in immunotherapy to treat cancer. Clin Pharmacol Ther. 2018;103(4):540–4.
21. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–5.
22. June CH, O’Connor RS, Kawalekar OU, Ghaisseri S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5.
23. Fidler II. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3(6):453–8.
24. Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nat Immunol. 2013;14(10):986–95.
25. Chang E, Rosenberg SA. Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy. J Immunother. 2001;24(1):88–90.
26. Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res. 2017;5(5):417–24.
27. Funato T, Nomizo T, Kim YH. Liver metastasis is associated with poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. J Thorac Oncol. 2017;12(9):e140–1.
28. Jimenez-Sanchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, et al. Heterogeneous tumor-immune microenvironments during differentially growing metastases in an ovarian cancer patient. Cell. 2017;170(5):927–938.e920.
29. Hensel JA, Khattar V, Ashton R, Lee C, Siegal GP, Ponnazhagan S. Location of tumor affects local and distant immune cell type and number. Immum Inflamm Dis. 2017;5(1):85–94.
30. Devaud C, Westwood JA, John LB, Flynn JK, Paquette-Fielde S, Duong CP, Yong CS, Pergam HJ, Stacker SA, Achen MG, et al. Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Mol Ther. 2014;22(1):18–27.
31. Zhao X, Li L, Starr TK, Subramanian S. Tumor location impacts immune response in mouse models of colon cancer. Oncotarget. 2017;8(33):54775–87.
32. Lehmann B, Ribberg C, Bruun-Hansen BC, Ipsen-Escobedo A, Gordan S, Lehmann C, Hoerstrup S, Winkler T, Schaft N, Dudiak D, et al. Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response. Sci Immunol. 2017;2(7). https://doi.org/10.1126/sciimmunol.aah6413.
33. Zhang S, Huang WC, Zhang L, Zhang C, Lowery FJ, Ding Z, Guo H, Wang H, Huang S, Sahin AA, et al. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res. 2013;73(18):5764–74.
34. Lowery FJ, Yu D. Brain metastasis: unique challenges and open opportunities. Biochim Biophys Acta Rev Cancer. 2017;1867(1):49–57.
35. Smedby KE, Brandt L, Backlund ML, Blomqvist P. Brain metastasis admissions in Sweden between 1987 and 2006. Br J Cancer. 2009;101(11):1919–24.
36. Frisk G, Svensson T, Backlund LM, Lidbrink E, Blomqvist P, Smedby KE. Incidence and trends of breast cancer admissions among breast cancer patients in Sweden. Br J Cancer. 2012;106(11):1850–3.
37. Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Kosan M, Amin-Kroodi L, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival of patients with non-small cell lung cancer treated with nivolumab. J Thorac Oncol. 2017;12(9):e140–1.
38. Lin NU, Prowell T, Tan AR, Kozak M, White J, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Kosan M, Amin-Kroodi L, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival of patients with non-small cell lung cancer treated with nivolumab. J Thorac Oncol. 2017;12(9):e140–1.
Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687–92.

Berghoff AS, Inan C, Ricken G, Widhalm G, Dieckmann K, Birner P, Obemforer F, Dome B, Bartsch R, Zielinski C, et al. 1324PTUMOR-infiltrating lymphocytes (TILS) and PD-L1 expression in non-small cell lung cancer brain metastases (BM) and matched primary tumors (PT). Ann Oncol. 2014;25(4):465–6.

Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Grl B, Bohn KA, Adkins CE, Roberts A, Thorstein HR, Gaasch JA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 2010;16(23):5664–78.

June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73.

Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, et al. endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404–19.

Morgalin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459–65.

Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsioris AJ, Cohen J, Vortmeyer A, Jilaveanu L, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976–83.

Tawbi HA, Foryth PA, Algazi A, Hamid O, Hodis FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722–30.

Zhang CH, Pearce EL. Emerging concepts of T cell metabolism as a target of immunotherapy. Nat Immunol. 2016;17(4):364–8.

Schapray NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL, Delgoffe GM. The tumor microenvironment represses T cell mitochondrial bioenergetics to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity. 2016;45(2):346–60.

Weinberg SE, Sena LA, Chandel NS. Mitochondria in the regulation of innate and adaptive immunity. Immunity. 2015;42(3):406–17.

Ron-Harel N, Santos D, Pechgurovic JM, Sage PT, Reddy A, Lovitch SB, Dephoure N, Satterstrom FK, Sheffer M, Spinielli JB, et al. Mitochondrial bioenergetics and proteome remodeling promote one-carbon metabolism for T cell activation. Cell Metab. 2016;24(1):104–17.

Mills E, Kelly B, O’Neill LAJ. Mitochondria are the powerhouse of immunity. Nat Immunol. 2017;18(5):488–98.

Rambold AS, Pearce EL. Mitochondrial dynamics at the interface of immune cell metabolism and function. Trends Immunol. 2018;39(1):6–18.

Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, Wang CR, Weinberg SE, Sena LA, Chandel NS. Mitochondrial bioenergetics and proteome remodeling promote one-carbon metabolism for T cell activation. Cell Metab. 2016;24(1):104–17.

Mills E, Kelly B, O’Neill LAJ. Mitochondria are the powerhouse of immunity. Nat Immunol. 2017;18(5):488–98.

Rambold AS, Pearce EL. Mitochondrial dynamics at the interface of immune cell metabolism and function. Trends Immunol. 2018;39(1):6–18.

Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, Wang CR, Weinberg SE, Sena LA, Chandel NS. Mitochondrial bioenergetics and proteome remodeling promote one-carbon metabolism for T cell activation. Cell Metab. 2016;24(1):104–17.

Mills E, Kelly B, O’Neill LAJ. Mitochondria are the powerhouse of immunity. Nat Immunol. 2017;18(5):488–98.

Rambold AS, Pearce EL. Mitochondrial dynamics at the interface of immune cell metabolism and function. Trends Immunol. 2018;39(1):6–18.

Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, Wang CR, Weinberg SE, Sena LA, Chandel NS. Mitochondrial bioenergetics and proteome remodeling promote one-carbon metabolism for T cell activation. Cell Metab. 2016;24(1):104–17.

Mills E, Kelly B, O’Neill LAJ. Mitochondria are the powerhouse of immunity. Nat Immunol. 2017;18(5):488–98.

Rambold AS, Pearce EL. Mitochondrial dynamics at the interface of immune cell metabolism and function. Trends Immunol. 2018;39(1):6–18.